BCM
REGN icon

Bluefin Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Bluefin Capital Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-30,500
Closed -$75K – 631
2019
Q4 		$75K Buy
+30,500
New +$10.3M 0.01% 434

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Harris Associates
Harris Associates Chicago, Illinois $75B AUM 11.27% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

Bluefin Capital Management's REGN Position: Q3 2015 in Review

Bluefin Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2015, closing a stake of 900 shares — an estimated $459K sold.

Bluefin Capital Management first reported a position in REGN in Q2 2015 and held it in 1 quarter. The position peaked at $459K in Q2 2015. 562 funds tracked by Wall St. Rank hold REGN as of Q3 2015.

  • Bluefin Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Bluefin Capital Management sold 900 Regeneron Pharmaceuticals shares in Q3 2015, an estimated $459K.
  • Bluefin Capital Management first reported a position in Regeneron Pharmaceuticals in Q2 2015 and held it in 1 quarter.
  • Bluefin Capital Management's Regeneron Pharmaceuticals position peaked at $459K in Q2 2015.
  • 562 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2015.

Based on Bluefin Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.